Who are ACB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hympavzi, Eliquis, Xarelto, Heparin Sodium In Plastic Container, Antithrombin III, Rivaroxaban, dabigatran, apixaban, or edoxaban.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acb.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ACB — Competitive Intelligence Brief

ACB (ACB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Factor Xa inhibitor. Area: Cardiovascular.

marketed Factor Xa inhibitor Factor Xa Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ACB (ACB) — NYU Langone Health. ACB is an anticoagulant that works by inhibiting Factor Xa.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ACB TARGET	ACB	NYU Langone Health	marketed	Factor Xa inhibitor	Factor Xa
Hympavzi	MARSTACIMAB	Pfizer Inc	marketed	Monoclonal Antibody	Factor Xa	2025-01-01
Eliquis	apixaban	Bristol-Myers Squibb	marketed	Factor Xa inhibitor	Factor Xa (FXa)	2012-01-01
Xarelto	rivaroxaban	Johnson & Johnson	marketed	Direct Factor Xa Inhibitor	Factor Xa (FXa)	2011-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anti-coagulant	Antithrombin III, Factor Xa, Factor IIa	1939-01-01
Antithrombin III	Antithrombin III	Octapharma	marketed	Anticoagulant; plasma-derived protease inhibitor	Thrombin (Factor IIa); Factor Xa
Rivaroxaban, dabigatran, apixaban, or edoxaban	Rivaroxaban, dabigatran, apixaban, or edoxaban	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Direct oral anticoagulant (DOAC)	Factor Xa (rivaroxaban, apixaban, edoxaban) or Thrombin (dabigatran)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-02-17 — Xarelto · 9539218 · Method of Use · US
2034-08-17 — Xarelto · 9539218*PED · Compound · US

Sponsor landscape (Factor Xa inhibitor class)

GlaxoSmithKline · 4 drugs in this class
Bayer · 2 drugs in this class
China National Center for Cardiovascular Diseases · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Kim, Seok Jin · 1 drug in this class
NYU Langone Health · 1 drug in this class
Paul Di Cesare,MD · 1 drug in this class
Pfizer · 1 drug in this class
Queen Mary University of London · 1 drug in this class
Queen's University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACB — Competitive Intelligence Brief. https://druglandscape.com/ci/acb. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab